Company Profile
Since its foundation in 1958 as a company specialized in the manufacture of products for veterinary use, the Group has undergone a continuous process of growth, diversification and internationalization, becoming today a pharmaceutical group of animal and human health reference, which stands out as:
- Manufacturer of a broad catalog of proprietary generic products for animal and human health, among which Fosfomycin Trometamol (generic antibiotic for urinary tract infections) stands out in human health.
- CDMO (Contract Development and Manufacturing Organization), which provides services for third parties in the development and manufacture of drugs in a wide variety of presentations, specializing in sterile, lyophilized and biological pharmaceutical forms.
Currently, Labiana has 4 operating companies, 464 employees, 6 manufacturing plants (Serbia and Spain) with the capacity to absorb the expected growth, a portfolio of its own drugs with more than 50 products marketed in more than 150 countries and more than 300 customers, all leading national and international pharmaceutical groups, including several multinationals with which it has a relationship of more than 15 years.
From 1980 until 1999, Labiana was part of the BASF Group and became BASF LABIANA, a period during which it developed vitamin injectables that made it one of the leading manufacturers of injectables for animal health in Europe, a position it still holds.
Its vocation for service and the conviction that animal and human health are interdependent and linked to the ecosystems in which they coexist, led it in 2002 to incorporate the human health pharmaceutical division and since then it has continued to grow with a focus on the 'One health/Una sola salud' principle.
With this same philosophy, in 2019 it incorporated the Serbian Veterinarski Zavod Subotica into the Group, which has opened the door to the high value-added segment of biologics (vaccines) in the field of animal health, enabling it to complete its product portfolio and provide a broader service to its customers.
Additionally, the company acquired in Turkey Zoleant Pharmaceuticals International also in 2019, which allows it to expand its own product portfolio and access new markets. Finally, the company launched its companion animal division, LabianaPets, in 2019, broadening the product commercialization focus.
BME Growth
